Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


February 15, 2001 15 February, 2001

Eldon Smith MD Appointed to Pheromone Sciences Board of Directors


Toronto, Ontario (February 15, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Eldon R. Smith, MD, FRCP(C), FACC, to its Board of Directors.

Dr. Eldon Smith brings a wealth of knowledge in medical research and extensive healthcare experience to Pheromone Sciences Board of Directors. He is presently Professor at the University of Calgary Medical School, where he was formerly the Dean of the Faculty of Medicine, and previously head of the Department of Medicine and head of the Division of Cardiology. Dr. Smith is a leading clinician and research scientist who has made major contributions to the Canadian cardiology and medical communities. He has served as President of the Canadian Cardiovascular Society, Chairman of the Scientific Grant Review Committee of the Heart and Stroke Foundation, and President of the Association of Canadian Medical Colleges. He is currently a Trustee of the Alberta Heritage Foundation for Medical Research and a member of the Premier's Advisory Council on Health for the Province of Alberta. He is also President of the Peter Lougheed Medical Research Foundation.

In addition to his medical practice, Dr Smith serves on the Board of Directors of a number of public companies including Canadian Natural Resources Ltd, Vasogen Inc. and BioMax Technologies Inc. He also serves on the Advisory Boards of the Canadian Medical Discovery Fund and a number of Biotechnology and Pharmaceutical Companies.

"Dr. Smith is a powerful addition to the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Eldon brings a rare combination of clinical, medical and business experience. Eldon has been used extensively by several of Canada's top funds to evaluate and mentor companies from inception to commercialization."

The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Charles Borg PhD. Mr. Borg remains a member of senior management retaining the position Executive Vice- President and Chief Operating Officer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.